Cargando…

A systematic survey of randomised trials that stopped early for reasons of futility

BACKGROUND: Randomised trial protocols may incorporate interim analyses, with the potential to stop the study for futility if early data show insufficient promise of a treatment benefit. Previously, we have shown that this approach will theoretically lead to mis-estimation of the treatment effect. W...

Descripción completa

Detalles Bibliográficos
Autores principales: Walter, S. D., Han, H., Guyatt, G. H., Bassler, D., Bhatnagar, N., Gloy, V., Schandelmaier, S., Briel, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966801/
https://www.ncbi.nlm.nih.gov/pubmed/31948397
http://dx.doi.org/10.1186/s12874-020-0899-1
_version_ 1783488818785026048
author Walter, S. D.
Han, H.
Guyatt, G. H.
Bassler, D.
Bhatnagar, N.
Gloy, V.
Schandelmaier, S.
Briel, M.
author_facet Walter, S. D.
Han, H.
Guyatt, G. H.
Bassler, D.
Bhatnagar, N.
Gloy, V.
Schandelmaier, S.
Briel, M.
author_sort Walter, S. D.
collection PubMed
description BACKGROUND: Randomised trial protocols may incorporate interim analyses, with the potential to stop the study for futility if early data show insufficient promise of a treatment benefit. Previously, we have shown that this approach will theoretically lead to mis-estimation of the treatment effect. We now wished to ascertain the importance of this phenomenon in practice. METHODS: We reviewed the methods and results in a set of trials that had stopped for futility, identified through an extensive literature search. We recorded clinical areas, interventions, study design, outcomes, trial setting, sponsorship, planned and actual treatment effects, sample sizes; power; and if there was a data safety monitoring board, or a published protocol. We identified: if interim analyses were pre-specified, and how many analyses actually occurred; what pre-specified criteria might define futility; if a futility analysis formed the basis for stopping; who made the decision to stop; and the conditional power of each study, i.e. the probability of statistically significant results if the study were to continue to its complete sample size. RESULTS: We identified 52 eligible trials, covering many clinical areas. Most trials had multiple centres, tested drugs, and 40% were industry sponsored. There were 75% where at least one interim analysis was planned a priori; a majority had only one interim analysis, typically with about half the target total sample size. A majority of trials did not pre-define a stopping rule, and a variety of reasons were given for stopping. Few studies calculated and reported low conditional power to justify the early stop. When conditional power could be calculated, it was typically low, especially under the current trend hypothesis. However, under the original design hypothesis, a few studies had relatively high conditional power. Data collection often continued after the interim analysis. CONCLUSIONS: Although other factors will typically be involved, we conclude that, from the perspective of conditional power, stopping early for futility was probably reasonable in most cases, but documentation of the basis for stopping was often missing or vague. Interpretation of truncated trials would be enhanced by improved reporting of stopping protocols, and of their actual execution.
format Online
Article
Text
id pubmed-6966801
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-69668012020-01-22 A systematic survey of randomised trials that stopped early for reasons of futility Walter, S. D. Han, H. Guyatt, G. H. Bassler, D. Bhatnagar, N. Gloy, V. Schandelmaier, S. Briel, M. BMC Med Res Methodol Research Article BACKGROUND: Randomised trial protocols may incorporate interim analyses, with the potential to stop the study for futility if early data show insufficient promise of a treatment benefit. Previously, we have shown that this approach will theoretically lead to mis-estimation of the treatment effect. We now wished to ascertain the importance of this phenomenon in practice. METHODS: We reviewed the methods and results in a set of trials that had stopped for futility, identified through an extensive literature search. We recorded clinical areas, interventions, study design, outcomes, trial setting, sponsorship, planned and actual treatment effects, sample sizes; power; and if there was a data safety monitoring board, or a published protocol. We identified: if interim analyses were pre-specified, and how many analyses actually occurred; what pre-specified criteria might define futility; if a futility analysis formed the basis for stopping; who made the decision to stop; and the conditional power of each study, i.e. the probability of statistically significant results if the study were to continue to its complete sample size. RESULTS: We identified 52 eligible trials, covering many clinical areas. Most trials had multiple centres, tested drugs, and 40% were industry sponsored. There were 75% where at least one interim analysis was planned a priori; a majority had only one interim analysis, typically with about half the target total sample size. A majority of trials did not pre-define a stopping rule, and a variety of reasons were given for stopping. Few studies calculated and reported low conditional power to justify the early stop. When conditional power could be calculated, it was typically low, especially under the current trend hypothesis. However, under the original design hypothesis, a few studies had relatively high conditional power. Data collection often continued after the interim analysis. CONCLUSIONS: Although other factors will typically be involved, we conclude that, from the perspective of conditional power, stopping early for futility was probably reasonable in most cases, but documentation of the basis for stopping was often missing or vague. Interpretation of truncated trials would be enhanced by improved reporting of stopping protocols, and of their actual execution. BioMed Central 2020-01-16 /pmc/articles/PMC6966801/ /pubmed/31948397 http://dx.doi.org/10.1186/s12874-020-0899-1 Text en © The Author(s). 2020 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Walter, S. D.
Han, H.
Guyatt, G. H.
Bassler, D.
Bhatnagar, N.
Gloy, V.
Schandelmaier, S.
Briel, M.
A systematic survey of randomised trials that stopped early for reasons of futility
title A systematic survey of randomised trials that stopped early for reasons of futility
title_full A systematic survey of randomised trials that stopped early for reasons of futility
title_fullStr A systematic survey of randomised trials that stopped early for reasons of futility
title_full_unstemmed A systematic survey of randomised trials that stopped early for reasons of futility
title_short A systematic survey of randomised trials that stopped early for reasons of futility
title_sort systematic survey of randomised trials that stopped early for reasons of futility
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966801/
https://www.ncbi.nlm.nih.gov/pubmed/31948397
http://dx.doi.org/10.1186/s12874-020-0899-1
work_keys_str_mv AT waltersd asystematicsurveyofrandomisedtrialsthatstoppedearlyforreasonsoffutility
AT hanh asystematicsurveyofrandomisedtrialsthatstoppedearlyforreasonsoffutility
AT guyattgh asystematicsurveyofrandomisedtrialsthatstoppedearlyforreasonsoffutility
AT basslerd asystematicsurveyofrandomisedtrialsthatstoppedearlyforreasonsoffutility
AT bhatnagarn asystematicsurveyofrandomisedtrialsthatstoppedearlyforreasonsoffutility
AT gloyv asystematicsurveyofrandomisedtrialsthatstoppedearlyforreasonsoffutility
AT schandelmaiers asystematicsurveyofrandomisedtrialsthatstoppedearlyforreasonsoffutility
AT brielm asystematicsurveyofrandomisedtrialsthatstoppedearlyforreasonsoffutility
AT waltersd systematicsurveyofrandomisedtrialsthatstoppedearlyforreasonsoffutility
AT hanh systematicsurveyofrandomisedtrialsthatstoppedearlyforreasonsoffutility
AT guyattgh systematicsurveyofrandomisedtrialsthatstoppedearlyforreasonsoffutility
AT basslerd systematicsurveyofrandomisedtrialsthatstoppedearlyforreasonsoffutility
AT bhatnagarn systematicsurveyofrandomisedtrialsthatstoppedearlyforreasonsoffutility
AT gloyv systematicsurveyofrandomisedtrialsthatstoppedearlyforreasonsoffutility
AT schandelmaiers systematicsurveyofrandomisedtrialsthatstoppedearlyforreasonsoffutility
AT brielm systematicsurveyofrandomisedtrialsthatstoppedearlyforreasonsoffutility